108,500.00
-700.00
(-0.64%)
As of 11:26:35 AM GMT+9. Market Open.
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
511,327,565.59
354,891,555.52
246,179,120.02
418,644,529.12
25,999,026.72
Cost of Revenue
51,197,759.68
34,082,497.21
37,768,133.59
22,335,994.40
1,974,010.33
Gross Profit
460,129,805.91
320,809,058.31
208,410,986.43
396,308,534.72
24,025,016.39
Operating Expense
323,169,262.00
358,331,255.00
339,489,015.00
301,350,334.00
263,523,840.00
Operating Income
362,130,812.91
-37,522,196.69
-131,078,028.57
94,958,200.72
-239,498,823.61
Net Non Operating Interest Income Expense
968,967.63
1,037,850.71
3,038,234.68
1,395,928.51
-2,341,250.99
Pretax Income
44,567,982.70
-43,857,762.62
-142,468,863.95
71,276,548.23
-239,909,329.41
Tax Provision
-4,742,119.55
-8,478,274.12
-3,037,986.27
6,430,907.91
7,504,284.45
Net Income Common Stockholders
57,382,505.86
-32,882,849.24
-139,430,878.00
64,845,640.00
-247,413,614.00
Basic EPS
789.41
-420.00
-1.78k
828.00
-3.45k
Diluted EPS
789.41
-420.00
-1.78k
828.00
-3.45k
Basic Average Shares
78,313.25
78,292.50
78,331.95
78,315.99
71,755.69
Diluted Average Shares
78,313.25
78,292.50
78,331.95
78,315.99
71,755.69
Total Operating Income as Reported
70,467,454.39
-37,522,197.04
-131,078,028.19
94,958,200.24
-239,498,823.79
Total Expenses
149,196,752.68
392,413,752.21
377,257,148.59
323,686,328.40
265,497,850.33
Net Income from Continuing & Discontinued Operation
57,382,505.86
-32,882,849.24
-139,430,878.00
64,845,640.00
-247,413,614.00
Normalized Income
55,244,087.02
-25,725,894.44
-127,045,850.86
66,687,197.99
-248,872,142.00
Interest Income
4,764,863.00
9,317,460.00
6,754,760.00
2,342,913.00
2,120,674.00
Interest Expense
2,282,593.00
8,279,609.00
3,716,526.00
946,984.00
4,461,927.00
Net Interest Income
968,967.63
1,037,850.71
3,038,234.68
1,395,928.51
-2,341,250.99
EBIT
353,257,158.70
-35,578,153.62
-138,752,337.95
72,223,532.23
-235,447,402.41
EBITDA
353,257,158.70
-20,260,709.62
-125,768,599.95
83,865,360.23
-224,588,685.41
Reconciled Cost of Revenue
51,197,759.68
34,082,497.21
37,768,133.59
22,335,994.40
1,974,010.33
Reconciled Depreciation
12,567,971.00
15,317,444.00
12,983,738.00
11,641,828.00
10,858,717.00
Net Income from Continuing Operation Net Minority Interest
57,382,505.86
-32,882,849.24
-139,430,878.00
64,845,640.00
-247,413,614.00
Total Unusual Items Excluding Goodwill
2,813,709.00
-8,872,034.00
-12,654,878.00
-2,024,190.00
1,944,704.00
Total Unusual Items
2,813,709.00
-8,872,034.00
-12,654,878.00
-2,024,190.00
1,944,704.00
Normalized EBITDA
350,443,449.70
-11,388,675.62
-113,113,721.95
85,889,550.23
-226,533,389.41
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
675,290.16
-1,715,079.20
-269,850.86
-182,632.01
486,176.00
12/31/2020 - 7/2/2020
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
603392.SS Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
68.09
-0.54%
300759.SZ Pharmaron Beijing Co., Ltd.
24.85
-2.20%
087010.KQ Peptron, Inc.
98,600.00
+1.23%
300122.SZ Chongqing Zhifei Biological Products Co., Ltd.
24.09
-0.90%
141080.KQ LigaChem Biosciences Inc.
120,600.00
-1.55%
028300.KQ HLB Co., Ltd.
80,300.00
+1.52%
4587.T PeptiDream Inc.
2,165.00
+0.84%
068270.KS Celltrion, Inc.
179,600.00
-0.33%
9939.HK Kintor Pharmaceutical Limited
0.890
-2.20%
7729.TWO SBI
20.55
0.00%